A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma

Phase 3 studies combining histone deacetylase inhibitors with bortezomib were hampered by gastrointestinal (GI) intolerance, which was not observed when combined with immunomodulatory drugs. This study is a single-center phase 2 study of panobinostat with lenalidomide and dexamethasone (FRD). Twenty...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Chari, Ajai, Cho, Hearn J., Dhadwal, Amishi, Morgan, Gillian, La, Lisa, Zarychta, Katarzyna, Catamero, Donna, Florendo, Erika, Stevens, Nadege, Verina, Daniel, Chan, Elaine, Leshchenko, Violetta, Laganà, Alessandro, Perumal, Deepak, Mei, Anna Huo-Chang, Tung, Kaity, Fukui, Jami, Jagannath, Sundar, Parekh, Samir
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728465/
https://ncbi.nlm.nih.gov/pubmed/29296798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017007427
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados